Shunt lock therapy with micafungin to treat shunt-associated Candida albicans meningitis in an infant

J Antimicrob Chemother. 2016 Jul;71(7):2060-1. doi: 10.1093/jac/dkw072. Epub 2016 Mar 23.

Authors

Cinzia Auriti¹, Fiammetta Piersigilli², Maria Paola Ronchetti², Francesca Campi², Paolina Giuseppina Amante³, Marco Falcone⁴, Bianca Maria Goffredo⁵

Affiliations

¹ Neonatal Intensive Care Unit, Department of Neonatology, Bambino Gesu' Children's Hospital, Rome, Italy cinzia.auriti@opbg.net.
² Neonatal Intensive Care Unit, Department of Neonatology, Bambino Gesu' Children's Hospital, Rome, Italy.
³ Neurosurgery Unit, Department of Neurosurgery, Bambino Gesu' Children's Hospital, Rome, Italy.
⁴ Infectious Diseases Section, Department of Public Health and Infectious Diseases, 'La Sapienza' University, Rome, Italy.
⁵ Laboratory of Biochemistry, Department of Specialist Pediatrics, Bambino Gesù Children's Hospital, Rome, Italy.

PMID: 27009029
DOI: 10.1093/jac/dkw072

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Intravenous
Antifungal Agents / administration & dosage
Antifungal Agents / therapeutic use*
Candida albicans / drug effects*
Candida albicans / growth & development
Candidiasis, Invasive / drug therapy*
Cerebrospinal Fluid Shunts / adverse effects*
Echinocandins / administration & dosage
Echinocandins / cerebrospinal fluid
Echinocandins / pharmacokinetics
Echinocandins / therapeutic use*
Humans
Infant, Newborn
Infant, Premature
Lipopeptides / administration & dosage
Lipopeptides / cerebrospinal fluid
Lipopeptides / pharmacokinetics
Lipopeptides / therapeutic use*
Male
Meningitis, Fungal / drug therapy*
Meningitis, Fungal / etiology
Micafungin

Substances

Antifungal Agents
Echinocandins
Lipopeptides
Micafungin